婴儿的成长,安全性和耐受性 米蛋白水解剂配方:GRITO随机对照试验
Anaïs Lemoine1, Antonio Nieto-García2, María Nieto-Cid2
1Service de Nutrition et Gastro-Entérologie Pédiatrique, Hôpital Armand Trousseau AP HP, Sorbonne Université, 75571 Paris, France.
Nutrients
|January 11, 2025
概括
化大米配方 (HRF) 支持牛奶蛋白过敏 (CMPA) 的婴儿的适当生长和耐受性获得,显示与广泛化配方 (eHF) 相比的安全性和有效性.
科学领域:
- 儿童营养学 儿童营养学
- 过敏和免疫学 过敏和免疫学
- 胃肠病学 胃肠病学
背景情况:
- 牛奶蛋白过敏 (CMPA) 影响了大量的婴儿.
- 化大米配方 (HRF) 是一个常见的替代品,但与广泛化配方 (eHF) 相比,存在增长问题.
研究的目的:
- 为了比较诊断为CMPA的婴儿在HRF或eHF食时的生长,安全性和耐受性获得.
- 为了评估不同配方的CMPA婴儿的人类测量和不良事件.
主要方法:
- 一个多中心,前性,随机,双盲,安慰剂受控试验.
- 105名患有CMPA的婴儿被随机分配给12个月的HRF或eHF.
- 主要结局:体重对长度Z分数的变化;次要结局:人体测量,耐受性,不良事件.
主要成果:
- 在HRF和eHF组之间,体重对长度Z分数没有显著差异 (p=0.28).
- 在这两组中,在所有人类学变量中观察到正常的生长模式.
- 类似的安全概况和耐受性,在HRF组中趋向于更快地获得耐受性.
结论:
- HRF是管理CMPA的安全有效选择,支持适当的生长和耐受性发展.
- 在CMPA的婴儿中,HRF表现出与eHF相似的结果.
- HRF可以被认为是CMPA管理中合适的替代方案.
相关概念视频
Teratogenicity
4.2K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
Bioavailability Study Design: Absolute Versus Relative Bioavailability
658
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
658
Bioavailability Study Design: Single Versus Multiple Dose Studies
388
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
388
Bioavailability Study Design: Healthy Subjects Versus Patients
252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
Drug Dosing: Infants and Children
1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
975
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
975


